Asset Details
Do you wish to reserve the book?
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Do you wish to request the book?
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
2019
Overview
The emergence of immune checkpoint inhibitors (ICIs), mainly including anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibodies (mAbs), has shaped therapeutic landscape of some type of cancers. Despite some ICIs have manifested compelling clinical effectiveness in certain tumor types, the majority of patients still showed de novo or adaptive resistance. At present, the overall efficiency of immune checkpoint therapy remains unsatisfactory. Exploring additional immune checkpoint molecules is a hot research topic. Recent studies have identified several new immune checkpoint targets, like lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), T cell immunoglobulin and ITIM domain (TIGIT), V-domain Ig suppressor of T cell activation (VISTA), and so on. The investigations about these molecules have generated promising results in preclinical studies and/or clinical trials. In this review, we discussed the structure and expression of these newly-characterized immune checkpoints molecules, presented the current progress and understanding of them. Moreover, we summarized the clinical data pertinent to these recent immune checkpoint molecules as well as their application prospects.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ Antigens
/ Antineoplastic Agents, Immunological - pharmacology
/ Antineoplastic Agents, Immunological - therapeutic use
/ B cells
/ Biomedical and Life Sciences
/ Cancer
/ CTLA-4 Antigen - antagonists & inhibitors
/ Genes
/ Humans
/ Immunomodulation - drug effects
/ LAG-3
/ Lymphocyte Activation - drug effects
/ Lymphocyte Activation - genetics
/ Lymphocyte Activation - immunology
/ Oncology
/ Programmed Cell Death 1 Receptor - antagonists & inhibitors
/ Review
/ T cells
/ T-Lymphocytes - drug effects
/ TIGIT
/ TIM-3
/ Tumors
/ VISTA
